News Digest / Ticker: ALT

Ticker: ALT

11:03am, Tuesday, Aug 12, 2025

Altimmune: Pemvidutide Phase 2b win and $183M cash bolster runway despite losses, dilution

Altimmune, Inc. (ALT) - quick read: late clinical‑stage biotech; pemvidutide Phase 2b (IMPACT) reported strong topline efficacy; company materially strengthened cash position in H1 2025 via equity raises and a term loan, but still reports no product revenue and substantial ongoing losses. All dol...

05:02pm, Tuesday, May 13, 2025

Altimmune Reports Narrowed Losses and Improved Cash Position Amidst Ongoing Clinical Trials